Gain Therapeutics, Inc. (GANX)
| Market Cap | 77.63M +43.6% |
| Revenue (ttm) | n/a |
| Net Income | -20.16M |
| EPS | -0.61 |
| Shares Out | 42.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 337,981 |
| Open | 1.850 |
| Previous Close | 1.870 |
| Day's Range | 1.810 - 1.889 |
| 52-Week Range | 1.410 - 4.340 |
| Beta | 0.15 |
| Analysts | Strong Buy |
| Price Target | 7.50 (+312.09%) |
| Earnings Date | May 22, 2026 |
About GANX
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company’s drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson’s... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for GANX stock is "Strong Buy." The 12-month stock price target is $7.5, which is an increase of 312.09% from the latest price.
News
Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026
BETHESDA, Md., April 24, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the...
Gain Therapeutics management to meet with Maxim
Analyst Jason McCarthy holds a meeting with management, April 22-23 hosted by Maxim.
Gain Therapeutics reports Q4 EPS (61c), consensus (14c)
Cash, cash equivalent and marketable securities were $20.8 million as of December 31, 2025, compared to $10.4M as of December 31, 2024. “We are encouraged by the progress made in
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update
BETHESDA, Md., March 26, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the...
Gain Therapeutics Transcript: The 38th Annual Roth Conference
A novel approach to Parkinson's targets disease biology by stabilizing GCase, with early clinical data showing safety, biomarker engagement, and stable motor scores. Phase II trials will stratify patients by biomarkers and begin in Q3, with further pipeline candidates in development.
Gain Therapeutics to Present at the 38th Annual ROTH Conference
BETHESDA, Md., March 19, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the...
Gain announces presentations on Phase 1b clinical study of GT-02287
Gain Therapeutics (GANX) announced the presentation of an oral presentation and poster at AD/PD 2026 International Conference on Alzheimer’s and Parkinson’s Disease and Related Neurological Disorders,...
Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026
Additional biomarker analysis reveals higher CSF levels of DOPA decarboxylase (DDC – an emerging PD biomarker) at baseline with a reduction following 90 days of dosing with GT-02287 in individuals wit...
Gain Therapeutics provides regulatory update on GT-02287
The Company submitted an IND to conduct a placebo-controlled, dose-range-finding Phase 2 clinical trial of GT-02287 in the United States. In March 2026, the Company submitted a response to the
Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update
Interim analysis of Phase 1b clinical study of GT-02287, including biomarker and clinical endpoints, will be presented in oral symposium Company remains on track to initiate Phase 2 clinical trial of ...
Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
BETHESDA, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...
Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week
BETHESDA, Md., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...
Gain Therapeutics Transcript: Study Update
GT-02287 showed promising biomarker and clinical signals in a phase 1b Parkinson's study, with reductions in CSF glucosylsphingosine correlating to UPDRS improvements. The drug's mechanism targets GCase pathway dysfunction, and further validation in phase II is planned.
Gain Therapeutics provides additional data from Phase 1b study of GT-02287
Gain Therapeutics (GANX) provided additional biomarker and clinical data from the Phase 1b clinical study of GT-02287 in people with Parkinson’s disease, PD, with or without a GBA1 mutation that
Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287
BETHESDA, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...
Gain Therapeutics holds a conference call
Management holds a KOL conference call with Drs. Alcalay and Lansbury to discuss the P1b Parkinson’s Disease data for GT-02287 on January 6 at 10 am. Webcast Link Published first
Gain Therapeutics price target raised to $10 from $6 at Roth Capital
Roth Capital raised the firm’s price target on Gain Therapeutics (GANX) to $10 from $6 and keeps a Buy rating on the shares. The firm says GT-02287 demonstrated blood-brain barrier
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease
BETHESDA, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...
Gain Therapeutic announces Phase 1b study of GT-02287 met prespecified endpoint
Gain Therapeutics (GANX) provided evidence, for the first time in Parkinson’s Disease, of a reduction in glucocerebrosidase substrate in cerebrospinal fluid. All individuals with elevated levels of gl...
Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson's Disease
Results showed CNS target engagement with reduction in GCase substrate glucosylsphingosine (GluSph) in cerebrospinal fluid (CSF), a prespecified endpoint The reduction in GluSph in CSF, a first-ever o...
Gain Therapeutics presents data on GT-02287
Gain Therapeutics (GANX) announced a poster presentation was made at the Society for Neuroscience annual meeting, Neuroscience 2025, held November 15th-19th in San Diego, CA. The poster outlined new e...
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025
GT-02287 reduces mitochondrial stress and enhances neuronal survival in MPP+ treated rat dopaminergic neurons GT-02287 decreases staining for MIRO1, suggesting improved mitochondrial health in α-synuc...
Gain Therapeutics reports Q3 EPS (15c), consensus (15c)
“We are encouraged by the progress made during the third quarter of 2025 and remain on track to report the analysis of both functional changes and biomarker activity during the
Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update
Presented initial data from Phase 1b study suggesting GT-02287 has a disease-slowing effect consistent with the preclinical models in vivo and the proposed mechanism of action Completed enrollment of ...
Gain Therapeutics to Present at Neuroscience 2025
BETHESDA, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...